Vitols S, Peterson C, Larsson O, Holm P, Aberg B
Department of Clinical Pharmacology, Karolinska Hospital, Stockholm, Sweden.
Cancer Res. 1992 Nov 15;52(22):6244-7.
In order to explore new treatment modalities for cancer, it is important to identify qualitative or quantitative differences in metabolic processes between normal and malignant cells. Previous in vitro and in vivo studies have shown that acute myelogenous leukemia cells have elevated receptor-mediated uptake of low density lipoproteins (LDL), compared to normal WBC. High receptor-mediated uptake of LDL by certain cancer cells in tissue culture and experimental tumors in animals in vivo has also been demonstrated. The present study was undertaken to compare the in vivo assimilation of LDL by human lung cancer tissue with that by surrounding lung tissue. Ten patients with newly diagnosed lung tumors, scheduled for surgery, received an i.v. injection of [14C]sucrose-labeled LDL. Following cellular uptake and degradation of the LDL particle, the radiolabeled sucrose moiety remains trapped in the lysosomal compartment, making this labeling technique useful for in vivo studies of tissue uptake of LDL. Radioactivity was determined in plasma and in tissue biopsies obtained at surgery 1-3 days after injection. The uptake of radioactivity in lung cancer tissue was elevated (1.5-3.0-fold), compared to surrounding tissue, in 7 of 9 patients with primary lung cancer. The most rapid preoperative disappearance of radioactivity from plasma was found in 2 patients with large tumors exhibiting high LDL uptake, relative to normal lung tissue. These findings support the hypothesis that the selectivity of cytotoxic agents can be enhanced also in nonhematological malignancies by administering the drugs incorporated in LDL particles.
为了探索癌症的新治疗方式,识别正常细胞与恶性细胞代谢过程中的定性或定量差异很重要。先前的体外和体内研究表明,与正常白细胞相比,急性髓性白血病细胞对低密度脂蛋白(LDL)的受体介导摄取增加。在组织培养和体内动物实验肿瘤中,某些癌细胞对LDL的高受体介导摄取也得到了证实。本研究旨在比较人肺癌组织与周围肺组织对LDL的体内同化情况。10例新诊断为肺部肿瘤且计划接受手术的患者接受了静脉注射[14C]蔗糖标记的LDL。在LDL颗粒被细胞摄取和降解后,放射性标记的蔗糖部分仍被困在溶酶体区室中,这使得该标记技术可用于LDL组织摄取的体内研究。在注射后1至3天手术时获取的血浆和组织活检样本中测定放射性。在9例原发性肺癌患者中的7例中,肺癌组织中的放射性摄取相对于周围组织升高(1.5至3.0倍)。在2例相对于正常肺组织表现出高LDL摄取的大肿瘤患者中,发现术前血浆中放射性消失最快。这些发现支持这样的假设,即通过给予掺入LDL颗粒中的药物,在非血液系统恶性肿瘤中也可以提高细胞毒性药物的选择性。